Tags

Type your tag names separated by a space and hit enter

Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.
Aliment Pharmacol Ther 2006; 23(11):1567-74AP

Abstract

BACKGROUND

Aminosalicylates are the mainstay of therapy to prevent relapse of quiescent ulcerative colitis. The rationale for using probiotics is based on the evidence implicating intestinal bacteria in the pathogenesis of this disorder.

AIM

To evaluate the efficacy of Lactobacillus GG alone or in combination with mesalazine vs. mesalazine as maintenance treatment in ulcerative colitis.

PATIENTS AND METHODS

187 ulcerative colitis patients with quiescent disease were randomized to receive Lactobacillus GG 18 x 10(9) viable bacteria/day (65 patients), mesalazine 2400 mg/day (60 patients) or Lactobacillus GG + mesalazine (62 patients). Disease activity index, endoscopic and histological scores were determined at 0, 6 and 12 months and in case of relapse. The primary end point was to evaluate sustained remission.

RESULTS

Overall analysis showed no difference in relapse rate at 6 (P = 0.44) and 12 months (P = 0.77) among the three treatment groups. However, the treatment with Lactobacillus GG seems to be more effective than standard treatment with mesalazine in prolonging the relapse-free time (P < 0.05).

CONCLUSIONS

Lactobacillus GG seems to be effective and safe for maintaining remission in patients with ulcerative colitis, and it could represent a good therapeutic option for preventing relapse in this group of patients.

Authors+Show Affiliations

Department of Internal Medicine, Catholic University of Rome, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16696804

Citation

Zocco, M A., et al. "Efficacy of Lactobacillus GG in Maintaining Remission of Ulcerative Colitis." Alimentary Pharmacology & Therapeutics, vol. 23, no. 11, 2006, pp. 1567-74.
Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23(11):1567-74.
Zocco, M. A., dal Verme, L. Z., Cremonini, F., Piscaglia, A. C., Nista, E. C., Candelli, M., ... Gasbarrini, A. (2006). Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology & Therapeutics, 23(11), pp. 1567-74.
Zocco MA, et al. Efficacy of Lactobacillus GG in Maintaining Remission of Ulcerative Colitis. Aliment Pharmacol Ther. 2006 Jun 1;23(11):1567-74. PubMed PMID: 16696804.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. AU - Zocco,M A, AU - dal Verme,L Zileri, AU - Cremonini,F, AU - Piscaglia,A C, AU - Nista,E C, AU - Candelli,M, AU - Novi,M, AU - Rigante,D, AU - Cazzato,I A, AU - Ojetti,V, AU - Armuzzi,A, AU - Gasbarrini,G, AU - Gasbarrini,A, PY - 2006/5/16/pubmed PY - 2006/9/30/medline PY - 2006/5/16/entrez SP - 1567 EP - 74 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 23 IS - 11 N2 - BACKGROUND: Aminosalicylates are the mainstay of therapy to prevent relapse of quiescent ulcerative colitis. The rationale for using probiotics is based on the evidence implicating intestinal bacteria in the pathogenesis of this disorder. AIM: To evaluate the efficacy of Lactobacillus GG alone or in combination with mesalazine vs. mesalazine as maintenance treatment in ulcerative colitis. PATIENTS AND METHODS: 187 ulcerative colitis patients with quiescent disease were randomized to receive Lactobacillus GG 18 x 10(9) viable bacteria/day (65 patients), mesalazine 2400 mg/day (60 patients) or Lactobacillus GG + mesalazine (62 patients). Disease activity index, endoscopic and histological scores were determined at 0, 6 and 12 months and in case of relapse. The primary end point was to evaluate sustained remission. RESULTS: Overall analysis showed no difference in relapse rate at 6 (P = 0.44) and 12 months (P = 0.77) among the three treatment groups. However, the treatment with Lactobacillus GG seems to be more effective than standard treatment with mesalazine in prolonging the relapse-free time (P < 0.05). CONCLUSIONS: Lactobacillus GG seems to be effective and safe for maintaining remission in patients with ulcerative colitis, and it could represent a good therapeutic option for preventing relapse in this group of patients. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/16696804/Efficacy_of_Lactobacillus_GG_in_maintaining_remission_of_ulcerative_colitis_ L2 - https://doi.org/10.1111/j.1365-2036.2006.02927.x DB - PRIME DP - Unbound Medicine ER -